aoncology.com (AONC): Debts to Book Capitalization

Graphic logo of American Oncology Network, Inc. (AONC)

The shortage of qualified oncologists creates staffing challenges that American Oncology Network (AONC) addresses through the implementation of advanced software and competitive offers. The historical debt-to-book capitalization ratio, where this metric equals 0.00, confirms financial stability. Stability is ensured by strict FDA control and exclusive insurance deals, as well as efficient IT outsourcing with strict SLA compliance.

American Oncology Network Inc (AONC) - Debts to Book Value from 02/21/2024 to 08/04/2024
Core merchandise of aoncology.com

American Oncology Network (AONC) effectively optimizes expenses through the digitalization of documentation and strict environmental control of its clinics. These operational successes impact net assets, which are weighed against the business's total liabilities in the formula. This metric determines the level of financial autonomy and the debt load risk in the event of a potential acquisition. It is critical for the investor that a balance is maintained between borrowed capital and the pace of expansion. The dynamics of the financial debt-to-book capitalization ratio confirm the stability of the liability structure.

Who American Oncology Network competes with

ONC - Debt to Book Capitalization Ratio|Debt to Book Value Ratio halozyme.com HALO|RVMD: Debts to Book Capitalization|AAPG - Debt to Book Value|Debts to Book Capitalization CGON|URGN (UroGen Pharma Corp) - Debts to Book Value|BCAX - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio personalis.com (PSNL)|Erasca (ERAS) - Debt to Book Value|Debt to Net Assets Ratio Delcath Systems Inc (DCTH)|YmAbs - Debts to Book Capitalization|AURA - Debt to Book Value|Candel - Debt to Book Value|ARAY: Debts to Book Capitalization|Debt to Book Capitalization Ratio sellaslifesciences.com SLS|Actuate Therapeutics Inc. (ACTU) - Debt to Net Assets Ratio|Debts to Book Capitalization CTOR (Citius Oncology, Inc)|Debts to Book Value TuHURA|Debts to Book Capitalization TARA|Debts to Book Capitalization FATE (fatetherapeutics.com)|Aadi Bioscience - Debt to Book Capitalization Ratio|Debt to Book Value TScan Therapeutics Inc TCRX|CSBR (Champions Oncology Corp) - Debts to Book Capitalization|XBIT: Debts to Book Value|Debt to Book Capitalization Ratio cel-sci.com CVM|ostherapies.com (OSTX) - Debt to Net Assets Ratio|RADX: Debts to Book Capitalization|Debts to Net Assets Artiva|Debts to Book Capitalization ANL (Adlai Nortye Ltd.)|Debt to Book Value Veru Corporation (VERU)|Debts to Book Capitalization TPST (Tempest Therapeutics)|Xilio Therapeutics Inc - Debts to Book Capitalization|Enochian BioSciences (RENB) - Debt to Book Capitalization Ratio|Mural Oncology plc (MURA) - Debt to Book Value Ratio|Debt to Book Value kairospharma.com KAPA|OKUR (OnKure Therapeutics) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio GDTC (CytoMed Therapeutics Ltd)|Debts to Book Value CRIS|Debt to Book Capitalization Ratio Apollomics, Inc. APLM|Debt to Book Value Ratio Tharimmune Inc (THAR)|Advanced Biomed - Debts to Book Capitalization|Genprex Inc - Debt to Book Value|CLDI (Calidi Bio) - Debt to Book Capitalization Ratio|SBFM: Debts to Book Value|xeneticbio.com (XBIO) - Debt to Book Capitalization Ratio|SLRX (Salarius Pharmaceuticals Inc) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio PPBT (Purple Biotech Corp)|Debts to Book Value BeiGene Ltd|CKPT: Debts to Book Capitalization|Debt to Net Assets elevationoncology.com ELEV|ICAD: Debt to Book Value|IKNA - Debts to Book Value|Debt to Book Value Notable Labs Inc. (NTBL)|VIRX: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio MorphoSys AG|nayabiosciences.com (NAYA) - Debt to Book Value Ratio|Debts to Book Capitalization AAPGV (Ascentage Pharma)